Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-1850
- Development stage
- Discontinued
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Percutaneous (bifurcated Needle)
01
Overview
TNX-1850 is a live virus vaccine candidate developed by Tonix Pharmaceuticals for the prevention of COVID-19. It is based on a recombinant horsepox virus vector engineered to express the spike protein from the SARS-CoV-2 BA.2 variant. The platform leverages the large packaging capacity and strong immunogenicity of horsepox-based vectors, aiming to induce robust T cell responses against SARS-CoV-2. This approach builds on prior work with related candidates such as TNX-1800 (expressing Wuhan strain spike) and is designed for percutaneous administration using a bifurcated needle, similar to historical smallpox vaccination methods[1][3][7]. As of 2024, development status appears discontinued[2].
- Brand names
- TNX-1850TNX1850TNX 1850
- Other names
- TNX-1850TNX1850TNX 1850
02
Targets
BA.2 S (SARS-CoV-2 BA.2 spike protein)
Beyond the preview
Go deeper on TNX-1850.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-1850.